HugoScore hugoscore.org

AI-enabled virtual primary care

InstaDoc

InstaDoc’s current homepage separates informational AI results from optional licensed-clinician care. It describes patient choices over escalation and onward sharing. Earlier pricing, prescribing, and legal findings remain historical because the detailed policies could not be refreshed.

AI-assisted draft Read full report Open directory

Published September 8, 2026 as an AI-assisted draft. The public report separates documented facts, agency judgments and unresolved questions.

82 /100 toward patient-directed
Agency posture Potentially agency-expanding, with clinical-governance, verification, and disclosure contradictions
The question we ask Who does InstaDoc serve in this deployment?
Control Patient-initiated AI intake with optional affiliated clinical care.
Agency read Potentially agency-expanding, with clinical-governance, verification, and disclosure contradictions
Vendor
InstaDoc, LLC; clinical services are described as provided by Panagea Medical Group, PC
Who it serves
Patient-directed, vendor-hosted AI symptom assessment with affiliated asynchronous clinical care
Primary User
U.S. adults seeking free symptom guidance and, where available, low-cost prescriptions, sick notes, or specialist referral letters
Control Model
Vendor-hosted public service. Controls and downstream processors depend on the assessed deployment.
Patient Impact
Symptom reflection and possible next steps may help patients prepare questions. The claim to use clinical references does not establish visible citations, calibrated uncertainty or validation for a particular answer.
Profile Status
AI-assisted draft
Last assessed
Sep 8, 2026
Review Confidence
Low to medium, current homepage only (AI-assisted draft)
AI / Model
OpenAI Codex / GPT-6
Human Review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Summary judgment · 82 out of 100 toward patient-directed

Patient-initiated AI intake with optional affiliated clinical care. Preserve the July 30 baseline of 82 and founder-profile submission provenance.

Potentially agency-expanding, with clinical-governance, verification, and disclosure contradictions

InstaDoc’s current homepage separates informational AI results from optional licensed-clinician care. It describes patient choices over escalation and onward sharing. Earlier pricing, prescribing, and legal findings remain historical because the detailed policies could not be refreshed.

Patient agency

How this tool changes agency

Expands agency when

Symptom reflection and possible next steps may help patients prepare questions. The claim to use clinical references does not establish visible citations, calibrated uncertainty or validation for a particular answer.

Limits agency when

Legal verification requirements, detailed data path, state coverage, final prices, e-prescribing readiness and output correction could not be refreshed.

Patient agency assessment

Who sets and changes the goal?

Patient authority

Patients still define the initial problem and choose clinical escalation. The current homepage makes prepayment review and waiting-time choice more explicit. Whether patients can revise or contest the free AI assessment remains unresolved.

What can the patient understand, question, or do?

Critical capacity

Symptom reflection and possible next steps may help patients prepare questions. The claim to use clinical references does not establish visible citations, calibrated uncertainty or validation for a particular answer.

Can the patient evaluate the conditions of use?

Informed control

Current front-page scope is clearer than the prior urgent-care framing, but anonymity and no-training promises cannot be reconciled against inaccessible policy text in this pass. Clinical and software rights should remain distinct.

Text findings

Why is this tool included?

Brought to HugoScore through a founder-profile screenshot; not an endorsement

A screenshot of founder Jon Pangia's public LinkedIn profile brought InstaDoc to HugoScore's attention on 2026-07-30. The screenshot was treated as a lead, not evidence for product claims. Publishing this draft does not endorse the founder, vendor, medical group, or service.

Conditions of use

Published controls and their limits

Current front-page scope is clearer than the prior urgent-care framing, but anonymity and no-training promises cannot be reconciled against inaccessible policy text in this pass. Clinical and software rights should remain distinct.

What remains unknown?

Not tested or not established

Legal verification requirements, detailed data path, state coverage, final prices, e-prescribing readiness and output correction could not be refreshed.

Who evaluated this?

AI-assisted public-source draft

Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.

Sources checked

Source-specific findings and retrieval limitations are recorded in the full report.

Review provenance

Criteria

CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.

Reviewer

AI-assisted public-source reassessment prepared in OpenAI Codex.

AI / model

OpenAI Codex / GPT-6

Human review

Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Review date

2026-09-08

Limitations

Legal verification requirements, detailed data path, state coverage, final prices, e-prescribing readiness and output correction could not be refreshed. No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.

Review method

Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.

AI-assisted draft · Low to medium, current homepage only (AI-assisted draft)